# BeOne Medicines AG (ONC)

> Source: Nexqual · https://nexqual.com/ONC · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, BeOne Medicines AG (ONC), nexqual.com/ONC" · informational, not investment advice.

**Price:** USD 374.08 (+6.43% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 351.48 · day 356.61–375.64 · 52w 253.95–385.22 · market cap $42.6B · NMS

## Key facts
- Analysts: Buy (mean 1.78 on a 1–5 scale) (27 analysts), mean target USD 435.72 (range 370–528).
- Total return with dividends: 1Y +17.6% vs S&P 500 +18.1%; 5Y +4.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD 1.88, revenue estimate $1.76B.

## Analysts
Consensus Buy (mean 1.78 on a 1–5 scale), 27 analysts; mean target USD 435.72 (low 370, high 528).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Target raised | Outperform | $450 → $459 |
| 2026-10-07 | Truist Securities | Target raised | Buy | $418 → $420 |
| 2026-10-01 | JP Morgan | Target raised | Overweight | $425 → $445 |
| 2026-09-10 | Barclays | Target raised | Overweight | $407 → $415 |
| 2026-08-06 | TD Cowen | Target raised | Buy | $424 → $454 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $451 → $450 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $416 → $418 |
| 2026-08-06 | Guggenheim | Target raised | Buy | $420 → $430 |
| 2026-08-06 | Barclays | Target raised | Overweight | $403 → $407 |
| 2026-08-06 | Citizens | Target raised | Market Outperform | $396 → $405 |
| 2026-07-23 | JP Morgan | Target raised | Overweight | $415 → $425 |
| 2026-07-14 | Barclays | Target lowered | Overweight | $409 → $403 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +17.6% | +4.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +17.7% | +0.9% |
| Volatility (annualized) | 35.0% | 50.0% |
| Max drawdown | -31.1% (Nov 2025→Jun 2026) | -65.8% (Oct 2021→Apr 2024) |

## Peers (Biotechnology)
RVMD (Revolution Medicines, Inc.) USD 189.26 +0.44% · RPRX (Royalty Pharma plc) USD 59.62 +5.39% · ARGX (argenx SE) USD 846.27 +5.44% · ALNY (Alnylam Pharmaceuticals, Inc.) USD 234.03 +4.56% · ROIV (Roivant Sciences Ltd.) USD 34.04 +2.07% · GMAB (Genmab A/S) USD 37.82 +3.42%

## More
Full page: https://nexqual.com/ONC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt